

Victor A Levin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10842218/publications.pdf>

Version: 2024-02-01

154
papers

12,689
citations

25034

57
h-index

23533

111
g-index

156
all docs

156
docs citations

156
times ranked

7732
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 1999, 17, 2572-2572. | 1.6 | 850 |
| 2 | Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. <i>Journal of Medicinal Chemistry</i> , 1980, 23, 682-684. | 6.4 | 773 |
| 3 | Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse. <i>Journal of Clinical Oncology</i> , 1999, 17, 2762-2762. | 1.6 | 710 |
| 4 | Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1487-1495. | 0.8 | 611 |
| 5 | Malignant Gliomas: MR Imaging Spectrum of Radiation Therapy- and Chemotherapy-induced Necrosis of the Brain after Treatment. <i>Radiology</i> , 2000, 217, 377-384. | 7.3 | 607 |
| 6 | The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. <i>Cancer</i> , 1995, 75, 1151-1161. | 4.1 | 425 |
| 7 | Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2000, 18, 708-708. | 1.6 | 413 |
| 8 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. <i>International Journal of Radiation Oncology Biology Physics</i> , 1990, 18, 321-324. | 0.8 | 385 |
| 9 | Effect of bevacizumab on radiation necrosis of the brain. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 323-326. | 0.8 | 383 |
| 10 | Reoperation for Recurrent Glioblastoma and Anaplastic Astrocytoma. <i>Neurosurgery</i> , 1987, 21, 615-621. | 1.1 | 247 |
| 11 | Cognitive Function as a Predictor of Survival in Patients With Recurrent Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2000, 18, 646-646. | 1.6 | 246 |
| 12 | Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. <i>Journal of Neurosurgery</i> , 1986, 65, 654-658. | 1.6 | 225 |
| 13 | Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. <i>Journal of Neurosurgery</i> , 1987, 67, 864-873. | 1.6 | 203 |
| 14 | External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2 gliomas: NCOG study 6H-82-2. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991, 21, 601-606. | 0.8 | 198 |
| 15 | PET of malignant cerebral tumors after interstitial brachytherapy. <i>Journal of Neurosurgery</i> , 1988, 69, 830-838. | 1.6 | 186 |
| 16 | Phase II Trial of Temozolomide Plus the Matrix Metalloproteinase Inhibitor, Marimastat, in Recurrent and Progressive Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2002, 20, 1383-1388. | 1.6 | 184 |
| 17 | Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources. <i>Journal of Neurosurgery</i> , 1984, 60, 61-68. | 1.6 | 183 |
| 18 | Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. <i>Journal of Neurosurgery</i> , 1977, 47, 329-335. | 1.6 | 180 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. <i>Journal of Neurosurgery</i> , 1991, 74, 701-708. | 1.6 | 166 |
| 20 | Cell kinetic studies of in situ human brain tumors with bromodeoxyuridine. <i>Cytometry</i> , 1985, 6, 627-632. | 1.8 | 160 |
| 21 | Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. <i>Journal of Neuro-Oncology</i> , 1996, 30, 61-9. | 2.9 | 159 |
| 22 | Differentiation of Cerebral Radiation Necrosis from Tumor Recurrence by [¹⁸ F]FDG and ⁸² Rb Positron Emission Tomography. <i>Journal of Computer Assisted Tomography</i> , 1987, 11, 563-570. | 0.9 | 157 |
| 23 | Prognostic implications of the proliferative potential of low-grade astrocytomas. <i>Journal of Neurosurgery</i> , 1988, 69, 839-842. | 1.6 | 150 |
| 24 | Evaluation of malignant glioma patients during the postirradiation period. <i>Journal of Neurosurgery</i> , 1979, 50, 624-628. | 1.6 | 126 |
| 25 | Hyperfractionated radiation therapy for brain-stem glioma: a Phase II trial. <i>Journal of Neurosurgery</i> , 1989, 70, 691-700. | 1.6 | 116 |
| 26 | Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.... <i>Journal of Neuro-Oncology</i> , 2006, 78, 295-302. | 2.9 | 111 |
| 27 | Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1979, 5, 775-786. | 0.8 | 109 |
| 28 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. <i>Journal of Neurosurgery</i> , 1985, 63, 218-223. | 1.6 | 108 |
| 29 | Management of Hypothalamic Gliomas in Children: An Analysis of 33 Cases. <i>Neurosurgery</i> , 1990, 26, 242-247. | 1.1 | 102 |
| 30 | Heuristic modeling of drug delivery to malignant brain tumors. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1980, 8, 257-296. | 0.6 | 98 |
| 31 | The Treatment of Anaplastic Oligodendrogliomas and Mixed Gliomas. <i>Neurosurgery</i> , 1993, 32, 365-371. | 1.1 | 97 |
| 32 | Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. <i>Neuro-Oncology</i> , 2012, 14, 1511-1518. | 1.2 | 95 |
| 33 | A Phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. <i>Journal of Neurosurgery</i> , 1979, 51, 526-532. | 1.6 | 94 |
| 34 | Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. <i>Clinical Cancer Research</i> , 2003, 9, 981-90. | 7.0 | 92 |
| 35 | Pharmacokinetics of intracarotid artery ¹⁴ C-BCNU in the squirrel monkey. <i>Journal of Neurosurgery</i> , 1978, 48, 587-593. | 1.6 | 91 |
| 36 | Procarbazine hydrochloride in the treatment of brain tumors. <i>Journal of Neurosurgery</i> , 1974, 40, 365-371. | 1.6 | 89 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Imaging patterns of multifocal gliomas. <i>European Journal of Radiology</i> , 1993, 16, 163-170. | 2.6 | 88 |
| 38 | Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 4282-4289. | 1.6 | 79 |
| 39 | Long-term Anti-inflammatory and Antihistamine Medication Use and Adult Glioma Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1277-1281. | 2.5 | 79 |
| 40 | The application of brain capillary permeability coefficient measurements to pathological conditions and the selection of agents which cross the blood-brain barrier. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1976, 4, 499-519. | 0.6 | 78 |
| 41 | 5-Fluorouracil and 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) Followed by Hydroxyurea, Misonidazole, and Irradiation for Brain Stem Gliomas: A Pilot Study of the Brain Tumor Research Center and the Childrens Cancer Group. <i>Neurosurgery</i> , 1984, 14, 679-681. | 1.1 | 77 |
| 42 | Chemotherapy of Primary Brain Tumors. <i>Neurologic Clinics</i> , 1985, 3, 855-866. | 1.8 | 76 |
| 43 | Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. <i>Cancer</i> , 1989, 64, 2420-2423. | 4.1 | 76 |
| 44 | Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 75-83. | 0.8 | 75 |
| 45 | Csf polyamines: A new and important means of monitoring patients with medulloblastoma. <i>Cancer</i> , 1981, 47, 757-760. | 4.1 | 73 |
| 46 | Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 8, 285-91. | 2.3 | 73 |
| 47 | Anaplastic Oligodendrogliomas: Prognostic Factors for Tumor Recurrence and Survival. <i>Oncology</i> , 2003, 65, 259-266. | 1.9 | 72 |
| 48 | Computed Tomography in the Evaluation of Malignant Glioma Before and After Therapy. <i>Radiology</i> , 1976, 121, 85-88. | 7.3 | 66 |
| 49 | Hyperfractionated radiation therapy for gliomas of the brainstem in children and in adults. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 24, 599-610. | 0.8 | 66 |
| 50 | Different Changes in Protein and Phosphoprotein Levels Result from Serum Starvation of High-Grade Glioma and Adenocarcinoma Cell Lines. <i>Journal of Proteome Research</i> , 2010, 9, 179-191. | 3.7 | 66 |
| 51 | Extracellular space of the cerebral cortex of normothermic and hypothermic cats. <i>Experimental Neurology</i> , 1970, 27, 101-114. | 4.1 | 65 |
| 52 | Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. <i>Journal of Neurosurgery</i> , 1978, 49, 589-592. | 1.6 | 62 |
| 53 | Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 519-528. | 0.8 | 62 |
| 54 | 13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2004, 6, 253-258. | 1.2 | 61 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 266-273. | 1.2 | 61 |
| 56 | Chemotherapy of pediatric brain-stem tumors. <i>Journal of Neurosurgery</i> , 1981, 54, 721-725. | 1.6 | 60 |
| 57 | Supratentorial malignant gliomas of childhood. <i>Journal of Neurosurgery</i> , 1984, 60, 495-499. | 1.6 | 59 |
| 58 | Primary central nervous system lymphoma: a role for adjuvant chemotherapy. <i>Journal of Neuro-Oncology</i> , 1992, 14, 271-5. | 2.9 | 56 |
| 59 | Prognostic significance of the pretreatment CT scan on time to progression for patients with malignant gliomas. <i>Journal of Neurosurgery</i> , 1980, 52, 642-647. | 1.6 | 54 |
| 60 | Improvement in survival produced by sequential therapies in the treatment of recurrent medulloblastoma. <i>Cancer</i> , 1983, 51, 1364-1370. | 4.1 | 54 |
| 61 | Quantitative observations of the acute effects of X-irradiation on brain capillary permeability: Part I. <i>International Journal of Radiation Oncology Biology Physics</i> , 1979, 5, 1627-1631. | 0.8 | 53 |
| 62 | The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 85-91. | 0.8 | 53 |
| 63 | Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status. <i>Journal of Neuro-Oncology</i> , 2006, 80, 83-90. | 2.9 | 53 |
| 64 | Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine. <i>Journal of Neurosurgery</i> , 1988, 68, 383-387. | 1.6 | 52 |
| 65 | Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2008, 10, 216-222. | 1.2 | 52 |
| 66 | Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 122, 145-150. | 2.9 | 52 |
| 67 | The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin). <i>Journal of Neuro-Oncology</i> , 1997, 34, 145-151. | 2.9 | 50 |
| 68 | Modulation of Glioma Risk and Progression by Dietary Nutrients and Antiinflammatory Agents. <i>Nutrition and Cancer</i> , 2011, 63, 174-184. | 2.0 | 49 |
| 69 | Getting More Out of Survival Data by Using the Hazard Function. <i>Clinical Cancer Research</i> , 2014, 20, 1404-1409. | 7.0 | 48 |
| 70 | A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 127-135. | 0.8 | 47 |
| 71 | Pattern of recurrence of medulloblastoma after low-dose. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 30, 551-556. | 0.8 | 46 |
| 72 | Final report on the united states phase i clinical trial of the hypoxic cell radiosensitizer, misonidazole (RO-07-0582; NSC #261037). <i>Cancer</i> , 1981, 48, 1697-1704. | 4.1 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Tight-binding inhibitory sequences against pp60câ€³rcidentified using a random 15-amino-acid peptide library. FEBS Letters, 1996, 399, 237-240. | 2.8 | 41 |
| 74 | Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies. Neuro-Oncology, 2002, 4, 268-277. | 1.2 | 41 |
| 75 | Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab. Journal of Neuro-Oncology, 2017, 134, 325-330. | 2.9 | 41 |
| 76 | Poorly differentiated gliomas of the cerebellum. A study of 18 patients. Cancer, 1990, 65, 337-340. | 4.1 | 40 |
| 77 | Brain-tumor chemotherapy. Journal of Neurosurgery, 1977, 46, 155-164. | 1.6 | 37 |
| 78 | Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: The past decade and where we are heading. Neuro-Oncology, 1999, 1, 69-80. | 1.2 | 37 |
| 79 | Stereotactic Injection of DTI-015 into Recurrent Malignant Gliomas: Phase I/II Trial. Neoplasia, 2003, 5, 9-16. | 5.3 | 36 |
| 80 | Basis and Importance of SRC as a Target in Cancer. , 2004, 119, 89-119. | | 36 |
| 81 | Response and progression in recurrent malignant glioma. Neuro-Oncology, 1999, 1, 282-288. | 1.2 | 34 |
| 82 | Cysts in malignant gliomas. Journal of Neurosurgery, 1980, 53, 821-825. | 1.6 | 33 |
| 83 | Distribution of 5-Fluorouracil-2-14 C and Its Metabolites in a Murine Glioma2. Journal of the National Cancer Institute, 1972, 49, 1577-1584. | 6.3 | 31 |
| 84 | The Concept of Drug Dose for in Vitro Studies with Chemotherapeutic Agents. Radiation Research, 1978, 76, 441. | 1.5 | 31 |
| 85 | An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemotherapy and Pharmacology, 2011, 67, 971-983. | 2.3 | 31 |
| 86 | A systematic approach to the management of patients with brain metastases of known or unknown primary site. Cancer Chemotherapy and Pharmacology, 2012, 69, 1-13. | 2.3 | 31 |
| 87 | Phase II evaluation of dibromodulcitol in the treatment of recurrent medulloblastoma, ependymoma, and malignant astrocytoma. Journal of Neurosurgery, 1984, 61, 1063-1068. | 1.6 | 30 |
| 88 | Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. Cancer Chemotherapy and Pharmacology, 1989, 23, 301-307. | 2.3 | 29 |
| 89 | Correlation of p53 immunoreactivity and sequencing in patients with glioma. Molecular Carcinogenesis, 1996, 15, 1-4. | 2.7 | 28 |
| 90 | Clinical importance of eflornithine (Î±-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncology, 2018, 7, CNS16. | 3.0 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2011, 102, 273-280. | 2.9 | 26 |
| 92 | Combination of 6-Thioguanine, Procarbazine, Lomustine, and Hydroxyurea for Patients with Recurrent Malignant Gliomas. <i>Neurosurgery</i> , 1996, 39, 921-926. | 1.1 | 23 |
| 93 | Retreatment of pediatric brain tumors with radiation and misonidazole: Results of a CCSG/RTOG phase I/II study. <i>Cancer</i> , 1986, 58, 1636-1640. | 4.1 | 21 |
| 94 | Prognostic Significance of Bromodeoxyuridine Labeling in Primary and Recurrent Glioblastoma Multiforme. <i>Neurosurgery</i> , 1994, 35, 192-198. | 1.1 | 21 |
| 95 | Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures. <i>Proteome Science</i> , 2012, 10, 5. | 1.7 | 21 |
| 96 | Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. <i>Journal of Neuro-Oncology</i> , 2018, 136, 79-86. | 2.9 | 21 |
| 97 | A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors. <i>Journal of Neuro-Oncology</i> , 1988, 6, 319-23. | 2.9 | 20 |
| 98 | Relationship of octanol/water partition coefficient and molecular weight to cellular permeability and partitioning in s49 lymphoma cells. <i>Pharmaceutical Research</i> , 1984, 01, 259-266. | 3.5 | 19 |
| 99 | Alternative splicing of neurofibromatosis type 1 gene transcript in malignant brain tumors: PCR analysis of frozen-section mRNA. <i>Molecular Carcinogenesis</i> , 1992, 6, 83-87. | 2.7 | 19 |
| 100 | Combination of 6-Thioguanine, Procarbazine, Lomustine, and Hydroxyurea for Patients with Recurrent Malignant Gliomas. <i>Neurosurgery</i> , 1996, 39, 921-926. | 1.1 | 19 |
| 101 | Quantitative observations of the subacute effects of X irradiation on brain capillary permeability: Part II. <i>International Journal of Radiation Oncology Biology Physics</i> , 1979, 5, 1633-1635. | 0.8 | 18 |
| 102 | Chemotherapeutic approaches to brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 8, 125-131. | 2.3 | 18 |
| 103 | Clinical anticancer pharmacology: Some pharmacokinetic considerations. <i>Cancer Treatment Reviews</i> , 1986, 13, 61-76. | 7.7 | 18 |
| 104 | Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 1978, 1, 41-8. | 2.3 | 16 |
| 105 | Controversies in the treatment of low-grade astrocytomas and oligodendrogliomas. <i>Current Opinion in Oncology</i> , 1996, 8, 175-177. | 2.4 | 16 |
| 106 | Increased chromosomal instability in peripheral lymphocytes and risk of human gliomas. <i>Carcinogenesis</i> , 1999, 20, 811-815. | 2.8 | 16 |
| 107 | Role of bevacizumab therapy in the management of glioblastoma. <i>Cancer Management and Research</i> , 2010, 2, 97-104. | 1.9 | 16 |
| 108 | A Phase II Trial of Oral Melphalan in Recurrent Primary Brain Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1988, 11, 52-54. | 1.3 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Identification of allelic loss on chromosome arm 6p in human astrocytomas by arbitrarily primed polymerase chain reaction. , 1998, 22, 165-170. | | 15 |
| 110 | Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer, 2007, 7, 106. | 2.6 | 14 |
| 111 | A New Preclinical 3-Dimensional Agarose Colony Formation Assay. Technology in Cancer Research and Treatment, 2008, 7, 329-334. | 1.9 | 14 |
| 112 | Risk assessment for developing gliomas: a comparison of two cytogenetic approaches. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2001, 490, 35-44. | 1.7 | 13 |
| 113 | Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer, 2012, 118, 3599-3606. | 4.1 | 13 |
| 114 | CLINICAL PHARMACOLOGY OF THE NITROSOUREAS. , 1981, , 171-180. | | 13 |
| 115 | Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO+PCV chemotherapy. International Journal of Cancer, 2007, 121, 2279-2283. | 5.1 | 12 |
| 116 | Understanding brain penetrance of anticancer drugs. Neuro-Oncology, 2018, 20, 589-596. | 1.2 | 12 |
| 117 | Putrescine diffusion in cat brain and capillary permeability in rat brain: Relation to CSF putrescine levels in brain tumor patients. European Journal of Cancer, 1981, 17, 143-147. | 0.9 | 11 |
| 118 | Bacterial expression of an active tyrosine kinase from a protein A/truncated c-srcfusion protein. FEBS Letters, 1993, 327, 224-230. | 2.8 | 11 |
| 119 | Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors. Neuro-Oncology, 2001, 3, 241-245. | 1.2 | 11 |
| 120 | Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015. Journal of Neuro-Oncology, 2003, 62, 251-258. | 2.9 | 10 |
| 121 | CNS Anticancer Drug Discovery and Development: 2016 conference insights. CNS Oncology, 2017, 6, 167-177. | 3.0 | 10 |
| 122 | Are Gliomas Preventable?. , 2007, 174, 205-215. | | 10 |
| 123 | Pharmacokinetic approaches to drug distribution in the cerebrospinal fluid based on ventricular administration in beagle dogs. Journal of Pharmacokinetics and Pharmacodynamics, 1985, 13, 387-403. | 0.6 | 8 |
| 124 | Tissue-based Assay for Ornithine Decarboxylase to Identify Patients Likely to Respond to Difluoromethylornithine. Journal of Histochemistry and Cytochemistry, 2004, 52, 1467-1474. | 2.5 | 8 |
| 125 | Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients. Expert Review of Anticancer Therapy, 2008, 8, 733-741. | 2.4 | 8 |
| 126 | Personalized medicine in neuro-oncology. CNS Oncology, 2016, 5, 55-58. | 3.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | CNS toxicity and CSF pharmacokinetics of intraventricular DFMO and MGBC in beagle dogs. <i>Cancer Chemotherapy and Pharmacology</i> , 1984, 13, 200-205. | 2.3 | 7 |
| 128 | CHEMOTHERAPY OF RECURRENT BRAIN TUMORS. , 1981, , 259-268. | | 7 |
| 129 | The Treatment of Anaplastic Oligodendrogliomas and Mixed Gliomas. <i>Neurosurgery</i> , 1993, 32, 365-371. | 1.1 | 7 |
| 130 | Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience. <i>Blood</i> , 2012, 120, 3670-3670. | 1.4 | 7 |
| 131 | Blood Volume, Hematocrit and Pressure Relationships in the Isolated Perfused Dog Brain. <i>Stroke</i> , 1970, 1, 270-277. | 2.0 | 6 |
| 132 | Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1979, 5, 1573-1576. | 0.8 | 5 |
| 133 | Lipid peroxidation does not appear to be a factor in late radiation injury of the cervical spinal cord of rats. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 25, 67-72. | 0.8 | 5 |
| 134 | Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa124. | 0.7 | 5 |
| 135 | Peripheral Nerve Segmental Demyelination Induced by Intraneural Diphtheria Toxin Injection. <i>Archives of Neurology</i> , 1974, 30, 163. | 4.5 | 4 |
| 136 | Quantitative high-pressure liquid chromatographic procedure for the determination of plasma and tissue levels of 2,4-diamino-5-(3,4-dichlorophenyl)-6-methylpyrimidine (metoprine) and its application to the measurement of brain capillary permeability coefficients. <i>Journal of Chromatography A</i> , 1978, 156, 181-187. | 3.7 | 4 |
| 137 | Melding a New 3-Dimensional Agarose Colony Assay with the Emax Model to Determine the Effects of Drug Combinations on Cancer Cells. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 163-175. | 1.9 | 4 |
| 138 | Drug discovery in neuro-oncology: challenges in the path forward. <i>Neuro-Oncology</i> , 2018, 20, 435-436. | 1.2 | 3 |
| 139 | In Vitro Cytotoxic Effects of Dibromodulcitol in 9L Rat Brain Tumor Cells. <i>Pharmaceutical Research</i> , 1986, 03, 302-306. | 3.5 | 2 |
| 140 | Discovery, Development, and Testing of Substrates and Inhibitors of pp60C-SRC. <i>International Journal of Pharmacognosy</i> , 1995, 33, 27-34. | 0.2 | 2 |
| 141 | Lysate array analyses of signal transduction inhibitors in tumor cell lines. <i>Clinical Proteomics</i> , 2006, 2, 33-43. | 2.1 | 2 |
| 142 | Chemotherapy of Recurrent Pediatric Posterior Fossa Tumors. <i>Neurosurgery</i> , 1983, 30, 209-225. | 1.1 | 1 |
| 143 | How far will the Voyager® take us?. <i>CNS Oncology</i> , 2019, 8, CNS26. | 3.0 | 1 |
| 144 | Correlation of p53 immunoreactivity and sequencing in patients with glioma. <i>Molecular Carcinogenesis</i> , 1996, 15, 1-4. | 2.7 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Clinical Correlations of Cerebrospinal Fluid Polyamine Levels. , 1983, , 441-452. | | 1 |
| 146 | CLINICAL CHARACTERISTICS OF CANCER IN THE BRAIN AND SPINAL CORD. , 1981, , 167-197. | | 1 |
| 147 | Prognostic Significance of Bromodeoxyuridine Labeling in Primary and Recurrent Glioblastoma Multiforme. Neurosurgery, 1994, 35, 192-198. | 1.1 | 1 |
| 148 | Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells. Oncotarget, 2020, 11, 3933-3942. | 1.8 | 1 |
| 149 | Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory. Neurotherapeutics, 2022, 19, 1855-1868. | 4.4 | 1 |
| 150 | Chemotherapy as first line treatment for oligodendroglioma. Journal of Neuro-Oncology, 2008, 86, 361-362. | 2.9 | 0 |
| 151 | In Reply to Dr. Healy. International Journal of Radiation Oncology Biology Physics, 2008, 72, 629-630. | 0.8 | 0 |
| 152 | NEUROIMAGING IN NEURO-ONCOLOGY. CONTINUUM Lifelong Learning in Neurology, 2008, 14, 77-93. | 0.8 | 0 |
| 153 | Nitrosoureas: Clinical and Experimental Considerations in the Treatment of Brain Tumors. , 1976, , 277-283. | | 0 |
| 154 | Treatment of anaplastic oligodendrogliomas: should resources be used to codify the old or to create the new?. Oncology, 2013, 27, 322, 324. | 0.5 | 0 |